308 related articles for article (PubMed ID: 30231317)
21. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.
Jiménez I; Carabia J; Bobillo S; Palacio C; Abrisqueta P; Pagès C; Nieto JC; Castellví J; Martínez-Ricarte F; Escoda L; Perla C; Céspedes Torrez DH; Boix J; Purroy N; Puigdefàbregas L; Seoane J; Bosch F; Crespo M
J Neurooncol; 2020 Aug; 149(1):13-25. PubMed ID: 32691208
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis and management of primary central nervous system lymphoma.
Han CH; Batchelor TT
Cancer; 2017 Nov; 123(22):4314-4324. PubMed ID: 28950405
[TBL] [Abstract][Full Text] [Related]
23. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
T Low J; B Peters K
CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313
[TBL] [Abstract][Full Text] [Related]
24. Primary central nervous system lymphoma: current state of anti-CD20 therapy and appraisal of reported response criteria.
Siegal T
J Clin Neurosci; 2014 May; 21(5):709-15. PubMed ID: 24725453
[TBL] [Abstract][Full Text] [Related]
25. Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.
Zhai Y; Zhou X; Wang X
Ther Adv Med Oncol; 2022; 14():17588359221093745. PubMed ID: 35558005
[TBL] [Abstract][Full Text] [Related]
26. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T; Fukushima T
J Neurooncol; 2003 May; 63(1):87-95. PubMed ID: 12814260
[TBL] [Abstract][Full Text] [Related]
27. High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma.
Chamberlain MC
J Neurooncol; 2016 Feb; 126(3):545-50. PubMed ID: 26563190
[TBL] [Abstract][Full Text] [Related]
28. Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells.
Hayano A; Takashima Y; Yamanaka R
Int J Clin Oncol; 2019 Sep; 24(9):1020-1029. PubMed ID: 30993483
[TBL] [Abstract][Full Text] [Related]
29. Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review.
Nepal G; Khurana M; Bucheli DH; Bhandari S; Joshi U; Bhagat R; Rehrig JH; Pudasainee P; Shing YK; Ortiz JF; Ojha R; Gajurel BP; Quinonez J; Ruxmohan S; Albert T; Licata S; Stien J
Neurol Int; 2022 Jan; 14(1):99-108. PubMed ID: 35076567
[TBL] [Abstract][Full Text] [Related]
30. Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient.
Zou R; Zhou X; Liu H; Wang P; Xia F; Kang L; Yu L; Wu D; Jin Z; Qu C
Cancer Res Treat; 2023 Oct; 55(4):1363-1368. PubMed ID: 37321275
[TBL] [Abstract][Full Text] [Related]
31. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
32. Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.
Bojic M; Berghoff AS; Troch M; Agis H; Sperr WR; Widhalm G; Wöhrer A; Kalhs P; Preusser M; Rabitsch W
Eur J Haematol; 2015 Jul; 95(1):75-82. PubMed ID: 25546348
[TBL] [Abstract][Full Text] [Related]
33. Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development.
Tateishi K; Miyake Y; Nakamura T; Yamamoto T
Brain Tumor Pathol; 2021 Jul; 38(3):173-182. PubMed ID: 34255226
[TBL] [Abstract][Full Text] [Related]
34. GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL.
Takashima Y; Hamano M; Fukai J; Iwadate Y; Kajiwara K; Kobayashi T; Hondoh H; Yamanaka R
Sci Rep; 2020 May; 10(1):8435. PubMed ID: 32439996
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Primary CNS Lymphoma: Maximizing Clinical Benefit, Minimizing Neurotoxicity.
Song KW; Batchelor T
Curr Oncol Rep; 2021 Sep; 23(11):132. PubMed ID: 34524547
[TBL] [Abstract][Full Text] [Related]
36. Primary CNS lymphoma.
Batchelor T; Loeffler JS
J Clin Oncol; 2006 Mar; 24(8):1281-8. PubMed ID: 16525183
[TBL] [Abstract][Full Text] [Related]
37. Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances.
Schaff L; Nayak L; Grommes C
Leuk Lymphoma; 2024 Apr; ():1-13. PubMed ID: 38597202
[TBL] [Abstract][Full Text] [Related]
38. Sustained response following BTK inhibitors based treatment in HIV-related primary central nervous system lymphoma: case report.
Zhou Y; Wang X; Lin X; Wang J; Yan X; Wen Y
AIDS Res Ther; 2023 Aug; 20(1):63. PubMed ID: 37644480
[TBL] [Abstract][Full Text] [Related]
39. Primary central nervous system lymphoma: essential points in diagnosis and management.
Paydas S
Med Oncol; 2017 Apr; 34(4):61. PubMed ID: 28315229
[TBL] [Abstract][Full Text] [Related]
40. Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances.
Chihara D; Dunleavy K
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):73-79. PubMed ID: 33288483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
